Decision Time Looms for Biotech's Riskiest Bet
An offshoot of Bristol-Myers Squibb’s acquisition of Celgene will soon pay off $7 billion or go bust.
An offshoot of Bristol-Myers Squibb’s acquisition of Celgene will soon pay off $7 billion or go bust.